Search results for "Myocardial"

showing 10 items of 1323 documents

[Coronary microvascular dysfunction: past, present, and future of an evolving disease].

2017

Coronary atherosclerosis is the main cause of myocardial ischemia. Nevertheless 10-30% of patients with angina has angiographically normal coronary arteries. In the last 30 years, several studies showed that in these patients the symptoms can be caused by dysfunction of the coronary microcirculation. Coronary microvascular dysfunction (CMVD) occurring in patients affected by specific cardiac or systemic diseases may be due to mechanisms of the underlying disease. On the other hand, in several patients affected by angina with angiographically normal coronary arteries, there is no specific disease, and CMVD only is responsible for the clinical picture. This condition can be defined as leading…

Cardiac magnetic resonanceMicrocirculationCoronary Artery DiseaseMetabolic syndromeMyocardial blush gradeType 2 diabetes mellituTIMI frame countEchocardiographyCoronary CirculationHypertensionHumansCoronary microcirculationHumanForecastingGiornale italiano di cardiologia (2006)
researchProduct

[Diagnosis of coronary microvascualar dysfunction in diabetic patients with cardiac syndrome X: comparison by current methods].

2013

The study population included 208 patients with chest pain and uninjured coronary arteries that we split into two populations: diabetics (72 patients) and non-diabetics (136 patients). We split patients with chest pain and uninjured coronary arteries that had a myocardial scintigraphy into two populations: patients with positive scintigraphy and negative. We calculated, on angiographic images of each patient, stored on suitable digital supports, Timi Frame Count (TFC), Myocardial Blush Grade (MBG) and Total Myocardial Blush Score (TMBS) using the protocol described by Gibson and Yusuf. On the basis of Yusuf's experience we imagined a new index: the Total Timi Frame Count as the sum of the t…

Cardiac syndrome X chest pain coronary angiography diabetes mellitus microcirculation myocardial scintigraphyChest PainMicrocirculationReproducibility of ResultsCoronary DiseaseCoronary AngiographySeverity of Illness IndexElectrocardiographyPredictive Value of TestsRisk FactorsCoronary CirculationExercise TestHumansEmergency Service HospitalRadionuclide ImagingBlood Flow VelocityDiabetic AngiopathiesMicrovascular Angina
researchProduct

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right

2020

For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48–4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outco…

Cardiac transplantlcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiomyopathy030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineInternal medicineleft ventricular assist deviceDiseases of the circulatory (Cardiovascular) systemMedicine030212 general & internal medicineMyocardial infarctionStrokeHeart Failurebusiness.industryMortality rateAtrial fibrillationmedicine.diseaseequipment and supplieslcsh:RC666-701RC666-701Heart failureCirculatory systemCardiologydestination therapyCardiology and Cardiovascular MedicinebusinessDestination therapyEuropean Cardiology Review
researchProduct

Differential contribution of dead space ventilation and low arterial pCO2 to exercise hyperpnea in patients with chronic heart failure secondary to i…

2003

In chronic heart failure (CHF), the abnormally large ventilatory response to exercise (VE/VCO(2) slope) has 2 conceptual elements: the requirement of restraining arterial partial pressure of carbon dioxide (pCO(2)) from increasing (because of an increased ratio between increased physiologic dead space and tidal volume [VD/VT]) and the depression of arterial pCO(2) by further increased ventilation, which necessarily implies an important non-carbon dioxide stimulus to ventilation. We aimed to assess the contribution of these 2 factors in determining the elevated VE/VCO(2) slope in CHF. Thirty patients with CHF underwent cardiopulmonary exercise testing (age 65 +/- 11 years, left ventricular e…

Cardiomyopathy DilatedMalemedicine.medical_specialtyPartial PressureMyocardial IschemiaHyperpneaHypercapniaInternal medicineIdiopathic dilated cardiomyopathymedicineHumansTidal volumeAgedEjection fractionbusiness.industryVO2 maxRespiratory Dead SpaceCarbon DioxideMiddle Agedmedicine.diseasePulmonary AlveoliHeart failureExercise TestCardiologyBreathingFemaleAcidosis RespiratoryBlood Gas Analysismedicine.symptomPulmonary VentilationCardiology and Cardiovascular Medicinebusinesshuman activitiesHypercapniaThe American Journal of Cardiology
researchProduct

Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, str…

2003

Background: the effects of long-term administration of β-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) ≤0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had su…

Cardiomyopathy DilatedMalemedicine.medical_specialtyTime FactorsAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyRadionuclide angiographyDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathymedicineHumanscardiovascular diseasesMyocardial infarctionExerciseMetoprololEjection fractionVentricular Remodelingmedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyGated Blood-Pool ImagingHeartStroke VolumeAtrial fibrillationMiddle Agedmedicine.diseaseHeart failureExercise TestCardiologyFemaleCardiology and Cardiovascular MedicinebusinessMetoprololmedicine.drugEuropean Journal of Heart Failure
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

C1-esterase inhibitor in ischemia and reperfusion.

2002

Summary Myocardial injury from ischemia can be aggravated by reperfusion of the jeopardized area. The precise underlying mechanisms have not been clearly defined, but proinflammatory events including complement activation play important roles. Cardioprotection by complement inhibition inter alia C1-esterase-inhibitor (C1-INH) was examined in several experimental models and under clinical conditions with ischemia and reperfusion. C1-INH reduced local anaphylatoxin release revealing the importance of the classical complement pathway. Inhibition of local complement activation was accompanied by improvement of myocardial function and perfusion of the previously ischemic myocardium. Leukocyte en…

Cardiotonic AgentsImmunologyIschemiaMyocardial IschemiaMyocardial Reperfusion InjuryPharmacologyComplement C1 Inactivator ProteinsProinflammatory cytokineClassical complement pathwayIschemiamedicineImmunology and AllergyAnimalsHumansAnaphylatoxinComplement Pathway ClassicalCardioprotectionbusiness.industryHeartHematologymedicine.diseaseC1 esteraseComplement systemAnesthesiaModels AnimalbusinessPerfusionComplement C1 Inhibitor ProteinImmunobiology
researchProduct

Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of…

2015

Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprote…

CardiotoxinIschemic heart diseaseCardiologyMyocardial IschemiaPreconditioningMyocardial Reperfusion InjuryCardioprotectionRemote conditioningCardiotoxinsPostconditioningGene therapyMedicalHumansMyocardialIschemic PreconditioningSocieties MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning; Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies; Medical; Cardiology and Cardiovascular MedicineOxidative StreGenomicsGenetic TherapyCardioprotection Gene therapy Genomics Ischemic heart disease Postconditioning Preconditioning Remote conditioningCardiotoxicityOxidative StressCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioningItalyIschemic Preconditioning MyocardialGene TargetingGenomicSocietiesCardiology and Cardiovascular MedicineHuman
researchProduct

Baseline adherence to the Mediterranean diet and major cardiovascular events: Prevención con dieta mediterránea trial

2014

Lifestyle modification, particularly dietary changes, is the cornerstone of population-based strategies for cardiovascular disease (CVD) prevention.1 Recently the Prevención con Dieta Mediterránea (PREDIMED) study,2 a 5-year randomized primary prevention trial (isrctn.org Identifier: ISRCTN35739639), showed a 30% reduction in incident CVD with Mediterranean diet (MeDiet) intervention in comparison with a control diet. At quarterly visits throughout the study, a validated 14-item MeDiet screening tool (Table 1) was used to assess conformity with this dietary pattern.3 Close monitoring of adherence to dietary instructions for CVD prevention is difficult in the clinical setting. Short dietary …

Cardiovascular eventAdultMalemedicine.medical_specialtyMediterranean dietTreatment outcomeMyocardial InfarctionDiet Mediterraneanlaw.inventionMedicina preventivaMediterranean cookingRandomized controlled triallawInternal medicineVegetablesCuina mediterràniaInternal MedicinemedicineHumansNutsDeath sudden cardiacPatient complianceDiet Fat-RestrictedDieta mediterraneaAgedProportional Hazards ModelsPreventive medicinebusiness.industryMalalties cardiovascularsFollow up studiesMiddle AgedPrimary PreventionStrokeDeath Sudden CardiacTreatment OutcomeCardiovascular diseasesCardiovascular DiseasesSpainPatient ComplianceFemale2168-6106businessFollow-Up Studies
researchProduct

Langzeitverlauf über 10 Jahre nach Ballondilatation bei stabiler und instabiler Angina pectoris

2008

OBJECTIVE To assess the cardiac status of patients ten years after percutaneous transluminal coronary artery angioplasty (PTCA). PATIENTS AND METHODS Data of 534 patients (436 men, 98 women; mean age 53.2 +/- 8 years) in whom a PTCA had been performed between 1983 and 1986 were analysed, based on a questionnaire answered 121 +/- 11 months after the initial procedure. At the time of PTCA 184 patients (35%) had unstable angina, 350 (65%) stable angina. RESULTS 116 patients (63%) with unstable angina and 164 (47%) with stable angina had at least one cardiac event after the initial PTCA (repeat PTCA, bypass operation, myocardial infarction, death). None of these events occurred in 68 patients (…

Cardiovascular eventmedicine.medical_specialtyPercutaneousbusiness.industryUnstable anginaGeneral Medicinemedicine.diseasesurgical procedures operativeBypass operationInternal medicineCardiologyMedicineCoronary artery angioplastyIn patientcardiovascular diseasesMyocardial infarctionbusinessCardiac statusDMW - Deutsche Medizinische Wochenschrift
researchProduct